YKL-40, also called chitinase-3-like-1 protein, is an inflammatory biomarker that has been associated with disease severity in inflammatory and malignant diseases, including AML, multiple myeloma and lymphomas. The objective of the current study was to assess the prognostic value of pretransplant recipient and donor plasma YKL-40 concentrations in patients with AML (n = 624) or myelodysplastic syndrome (n = 157) treated with allogeneic hematopoietic cell transplantation (HCT). In recipients, the plasma YKL-40 concentrations were increased when the HCT-comorbidity index was ⩾ 5 (P = 0.028). There were no significant associations between plasma YKL-40 concentrations in recipients and any outcome measures. In donors with YKL-40 plasma concentrations above the age-adjusted 95th percentile, a trend toward increased grade II-IV acute GvHD in recipients was observed (adjusted hazard ratio 1.39 (95% confidence interval 1.00-1.94), P = 0.050), with no significant associations with overall survival, treatmentrelated mortality or relapse. In conclusion, our study shows that YKL-40 does not aid risk stratification of patients undergoing allogeneic HCT, but suggests that YKL-40 may aid donor selection when multiple, otherwise equal, donors are available.
INTRODUCTION YKL-40 (chitinase-3-like-1 protein (CHI3L1)) is an acute phase reactant, which is mainly secreted by cancer cells, 1 vascular smooth muscle cells, 2 connective tissue cells 3 and immune cells. 4, 5 Increased levels have been associated with poor prognosis in patients with different types of cancer and inflammatory diseases. 1, 3, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] YKL-40 has a role in angiogenesis, 17 inflammation 18 and its synthesis is stimulated by interleukin (IL)-6. 19 Compared with C-reactive protein (CRP), which is secreted by hepatocytes as response to IL-6, YKL-40 originates from cells directly involved in the disease process and has a different tempero-spatial secretion profile, 20, 21 and may therefore reflect disease activity more accurately.
We have previously investigated YKL-40 in hematopoietic cell transplantation (HCT) after nonmyeloablative conditioning. 22 Recipients with a pretransplant YKL-40 plasma concentration above the age-adjusted 95th percentile had a higher relapserelated mortality, and lower PFS and overall survival (OS), whereas recipients transplanted with donors with YKL-40 plasma concentration above the age-adjusted 95th percentile had increased probability of experiencing grade II-IV GvHD.
The objective of the current study was to validate the role of recipient and donor plasma YKL-40 as a prognostic biomarker in patients undergoing unrelated donor HCT for AML or myelodysplastic syndrome (MDS).
PATIENTS AND METHODS
The study cohort consisted of 781 donor/recipient pairs with AML or MDS undergoing allogeneic hematopoietic cell transplantation with bone marrow or G-CSF-mobilized PBSC from 7/8 or 8/8 allele (HLA-A, B, C and DRB1)-matched unrelated donors. Early stage disease was defined as AML in first CR or MDS with refractory anemia with or without ringed sideroblasts. Intermediate stage disease was defined as AML in second or subsequent CR or in first relapse. Advanced stage disease was defined as MDS subtype refractory anemia with excess blasts or in transformation, or MDS not otherwise specified. Transplantation demographics are shown in Table 1 Observational studies conducted by the CIBMTR are performed in compliance with the privacy rule (HIPAA) as a Public Health Authority and in compliance with all applicable federal regulations pertaining to the protection of human research participants as determined by the continuous review of the Institutional Review Board (IRB) of the National Marrow Donor Program.
Outcomes
OS was defined as time from HCT to death from any cause. Treatmentrelated mortality (TRM) was defined as death in continuous remission from 1 primary disease, with relapse as a competing risk. Disease-free survival was defined as time to death from any cause or relapse. Acute GvHD grades II-IV and III-IV were defined according to the Glucksberg scale. 23 Primary malignancy relapse was defined using CIBMTR criteria with death as a competing risk. 24 
YKL-40 plasma analysis
From the 781 included recipient/donor pairs, plasma was available from all recipients and 576 donors. Plasma was prepared from EDTAanticoagulated blood within 8 h of sampling and stored at − 80°C until YKL-40 analysis. YKL-40 concentrations are stable at room temperature in EDTA-anticoagulated blood for up to 8 h. 25 Plasma concentrations of YKL-40 were determined in duplicates using a commercial sandwich-type ELISA (Quidel, Santa Clara, CA, USA). The detection limit was 10 μg/L. The intra-assay coefficients of variation were 5% (at 40 μg/L), 4% (at 104 μg/L) and 4% (at 155 μg/L). The inter-assay coefficient of variation was o6%. Because YKL-40 levels vary with age, patients and donors were divided into subjects with normal plasma YKL-40 concentrations, that is, equal to or below the age-adjusted 95th percentile, and subjects with high YKL-40 concentrations, that is, above the age-adjusted 95th percentile. 26 
Statistics
The main variable, donor YKL-40 plasma concentration, was treated as a categorical variable with at or above versus below the age-adjusted 95th percentile, consistent with previous analyses in the transplant population. χ 2 or Fisher's exact tests were used to compare frequencies for categorical variables, and analysis of variance was used to compare means for continuous variables. Univariate probabilities for OS were calculated using the Kaplan-Meier estimator. 27 Comparison of survival curves was done using the log-rank test. The cumulative incidences of acute GvHD II-IV and TRM were calculated using a Taylor series linear approximation to estimate the variance. 28 Multivariate analysis was performed using Cox proportional hazards models. Only recipients and donors for whom complete data were available were included in the multivariate analyses, resulting in the inclusion of 745 recipients for testing the recipient plasma YKL-40 effect and 565 recipients for testing the donor plasma YKL-40 effect. First, we built preliminary multivariate models for OS, disease-free survival, relapse, TRM and acute GvHD II-IV and III-IV. All the clinical variables were tested for affirmation of the proportional hazards assumption. Factors that violated the proportional hazards assumption were adjusted through stratification. Then, a stepwise model-building procedure was used to develop models for each outcome with a threshold of 0.05 for both entry and retention in the model. On the basis of these preliminary models, the main variable was tested by forcing it into the models. Interactions between the main variable and the adjusted covariates were also tested at a significance level of 0.01, and no significant interactions were detected. SAS version9.3 (SAS Institute, Cary, NC, USA) was used for all the analyses. Table 2 shows associations between recipient mean plasma YKL-40 concentrations and pretransplant variables, and the proportion of recipients with plasma YKL-40 concentrations above the age-adjusted 95th percentile. Plasma was available from 781 recipients and 576 donors. The mean plasma YKL-40 concentration was 61 μg/L (range, 20-864) and correlated significantly with age both among donors (r 2 = 0.03, P o 0.001) and recipients (r 2 = 0.11, Po 0.001). No significant associations were observed between Karnofsky score and recipient mean plasma YKL-40 concentration (Table 2) . However, the proportion of recipients with plasma YKL-40 concentrations above the age-adjusted 95th percentile was highest in the subset of recipients who had a Karnofsky score o90 (Karnofsky score o 90, n = 72 (29%); Karnofsky ⩾ 90, n = 114 (23%); P = 0.059). Mean plasma YKL-40 concentrations were similar in recipients with HCT-comorbidity index between 0-4, and only increased significantly in recipients with HCT-comorbidity index ⩾ 5 (P = 0.028). There were no differences in mean plasma YKL-40 concentrations or proportion of recipients with plasma YKL-40 above the age-adjusted 95th Abbreviations: AML = acute myeloid leukemia; HCT-CI = hematopoietic cell transplantation comorbidity index; IPSS = international prognostic scoring system; MDS = myelodysplastic syndrome; NA = not applicable. Adjusted for disease, CMV match status, conditioning regimen and HLA match. Patients who had the donor plasma YKL-40 concentration missing (n = 205) were deemed ineligible for testing the donor plasma YKL-40 effect. In addition, 36 (or 11) patients were excluded in multivariate testing for recipient (or donor) plasma because of missing information on either the time-to-event end points or covariates that were adjusted in the models.
RESULTS
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B Kornblit et al percentile between recipients with AML or MDS ( Table 2 ). No differences in YKL-40 plasma concentrations or proportion of patients with YKL-40 plasma concentration above the age-adjusted 95th percentile were observed according to AML or MDS disease status, cytogenetics or international prognostic scoring system (Table 2) .
Associations between plasma YKL-40 concentrations and outcome Although plasma YKL-40 concentrations above the age-adjusted 95th percentile in donors or recipients in general were associated with hazard ratios 41 (Table 3) , no significant associations between donor plasma YKL-40 concentrations above the ageadjusted 95th percentile and grade III-IV acute GvHD, TRM, relapse, OS or disease-free survival were observed (Table 3) . However, a trend toward an association between donor plasma YKL-40 concentrations above the age-adjusted 95th percentile and recipient grade II-IV acute GvHD (adjusted hazard ratio 1.39, 95% confidence interval 1.00-1.94, P = 0.050 (Figure 1 ), was observed. When plasma YKL-40 concentrations were analyzed as a continuous value or dichotomized at the best cutpoint, conclusions were similar to the primary analysis (data not shown). The impact of extremely low plasma YKL-40 concentrations was also analyzed, however, no significant associations were observed (data not shown).
DISCUSSION
In contrast to our previous study, 22 no significant associations between recipient plasma concentrations of YKL-40 and relapserelated outcome measures were observed. The discrepancy can be explained by differences in diagnoses and remission status between patients included in the current and the previous study. Increased serum or plasma concentrations have been associated with disease severity in Hodgkin's 9 and non-Hodgkin's lymphomas, 29, 30 and in our previous study, approximately half of the recipients had a variety of lymphoid diseases in various stages of remission, allowing the association between plasma YKL-40, remission status and relapse to become evident. 22 Although YKL-40 has been shown to be secreted by myeloid leukemia cell lines, 5 a previous study of YKL-40 in AML demonstrated that increased YKL-40 serum concentrations prior to chemotherapy only were associated with lower survival due to infections, and not prognostic factors such as cytogenetics or FAB classification. 7 This may reflect that increased YKL-40 concentrations are associated with the degree of inflammation rather than the disease burden in AML. In line with these observations, high YKL-40 levels in in the current study were associated with high HCT-comorbidity index, but not with disease-related variables.
As the current study cohort was relatively homogenous, only consisting of patients with MDS and AML with low disease burden at the time of transplant, it was not possible to observe any association between recipient YKL-40 and relapse. It should be noted that the cohort in our previous study only included nonmyeloablative transplants. However, as there is no evidence to support that the function of YKL-40 is dependent on the conditioning regimen, there is no reason to believe that the observed differences in relapse-related outcome measures between our studies is related to differences in conditioning regimens.
Overall, no statistically significant findings between plasma concentrations of YKL-40 and outcome parameters were observed in the current study. However, a signal at the P = 0.05 level, in line with our previous finding in nonmyeloablative HCT, 22 was detected. Namely, a trend toward an association between donor plasma YKL-40 concentrations above the age-adjusted 95th percentile and increased incidence of grade II-IV acute GvHD.
Although no pathophysiological mechanism linking YKL-40 to GvHD has been described, observations from a knockout model of the murine analog of YKL-40 and BRP-39 may offer some explanation. 31 Knockout of BRP-39 entails defective IL-13-induced inflammatory responses, and increased apoptosis of macrophages and CD4 + T cells. In our setting with increased YKL-40 concentrations, an opposite reaction may be hypothesized with increased accumulation of macrophages, dendritic cells, T cells and enhanced IL-13-mediated inflammation, which previously has been associated with acute GvHD, 32 thus augmenting inflammatory and acute GvHD.
As plasma samples were only available from 576 of 781 donors, the risk of type I errors was increased. However, as missing samples were randomly distributed throughout the cohort, only overall statistical power was weakened, whereas bias due to skewing of the cohort was unlikely.
In conclusion, the main findings of the current study show that pretransplant plasma YKL-40 concentrations do not increase the fidelity of the overall risk assessment of patients with AML or MDS undergoing allogeneic HCT. However, a borderline significant association between the inflammatory state of the donor, at the time of donation, and grade II-IV acute GvHD was observed. In current practice, choosing the best donor for a patient is based on fairly blunt clinical criteria such as HLA match, blood type, age, gender and CMV serostatus. [33] [34] [35] [36] [37] Investigation of donor-specific parameters such as inflammatory state, immune responsiveness or other measures of the potential to be a safe and effective donor is another approach to try to improve the success of transplantation. In this context, donor YKL-40 plasma concentrations could be relevant in different transplant settings, such as in HLA-identical related donor transplants, where the inflammatory state of the donor could be of more importance due to the lower degree of inherent alloreactivity than in the unrelated donor setting. Plasma YKL-40 could also be of relevance in haploidentical transplants, where the inflammatory state of the donor could aid selection between a larger number of potential donors. To establish the role of YKL-40 in donor selection, further studies are needed. 
